Immuneering is a biopharmaceutical company focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases. Co.'s development programs in oncology is focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways. Co.'s lead oncology product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The IMRX stock yearly return is shown above.
The yearly return on the IMRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|